Jump to main content
eTG Complete
Index
Search
Home
Cardiovascular
Principles of anticoagulant therapy
Considerations for anticoagulation in patients with obesity
Cardiovascular
Atherosclerotic cardiovascular disease risk estimation
Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease
Lipid modification
Blood pressure reduction
Acute chest pain of possible cardiac origin
Acute coronary syndromes
Stable angina
Antithrombotic therapy after endovascular and cardiac interventions
Secondary prevention of atherosclerotic cardiovascular events
Peripheral artery disease
Pericarditis
Heart failure
Cardiac rehabilitation programs
Tachyarrhythmias
Bradyarrhythmias
Orthostatic hypotension
Pulmonary hypertension
Venous thromboembolism
Periprocedural management of patients with cardiovascular disease
Principles of anticoagulant therapy
General information about anticoagulant therapy
Patient education about anticoagulant therapy
Assessment of bleeding risk for anticoagulant therapy
Overview of parenteral anticoagulants
Heparin-induced thrombocytopenia
Practical information on using unfractionated heparin
Practical information on using low molecular weight heparin
Practical information on using danaparoid
Practical information on using fondaparinux
Practical information on using bivalirudin
Overview of oral anticoagulants
Practical information on using dabigatran
Practical information on using apixaban
Practical information on using rivaroxaban
Practical information on using warfarin
Bleeding and overanticoagulation in patients taking warfarin therapeutically
Considerations for anticoagulation in patients with obesity
General considerations for anticoagulation in patients with obesity
Anticoagulation for venous thromboembolism (VTE) in patients with obesity
Anticoagulation to prevent thromboembolic events in patients with atrial fibrillation and obesity
References
Considerations for anticoagulation in patients with obesity
Published
June 2023
General considerations for anticoagulation in patients with obesity
Anticoagulation for venous thromboembolism (VTE) in patients with obesity
Anticoagulation to prevent thromboembolic events in patients with atrial fibrillation and obesity
